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Abstract
Background
Metabolic factors are increasingly recognized to play an important role in the pathogenesis
of Alzheimer’s disease and dementia. Abnormal parathyroid hormone (PTH) levels play a
role in neuronal calcium dysregulation, hypoperfusion and disrupted neuronal signaling.
Some studies support a significant link between PTH levels and dementia whereas others
do not.
Methods
We conducted a systematic review through January 2014 to evaluate the association be-
tween PTH and parathyroid conditions, cognitive function and dementia. Eleven electronic
databases and citation indexes were searched including Medline, Embase and the
Cochrane Library. Hand searches of selected journals, reference lists of primary studies
and reviews were also conducted along with websites of key organizations. Two reviewers
independently screened titles and abstracts of identified studies. Data extraction and study
quality were performed by one and checked by a second reviewer using predefined criteria.
A narrative synthesis was performed due to the heterogeneity of included studies.
Results
The twenty-seven studies identified were of low and moderate quality, and challenging to
synthesize due to inadequate reporting. Findings from six observational studies were mixed
but suggest a link between higher serum PTH levels and increased odds of poor cognition
or dementia. Two case-control studies of hypoparathyroidism provide limited evidence for a
link with poorer cognitive function. Thirteen pre-post surgery studies for primary hyperpara-
thyroidism show mixed evidence for improvements in memory though limited agreement in
other cognitive domains. There was some degree of cognitive impairment and improvement
postoperatively in observational studies of secondary hyperparathyroidism but no evident
pattern of associations with specific cognitive domains.
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Conclusions
Mixed evidence offers weak support for a link between PTH, cognition and dementia due to
the paucity of high quality research in this area.
Introduction
In the absence of disease modifying or curative treatments, the identification of potentially
modifiable risk factors for Alzheimer’s disease and other dementia subtypes is particularly im-
portant. Parathyroid hormone (PTH) is of interest in relation to cognitive function and demen-
tia as it crosses the blood brain barrier and PTH receptors are found throughout the human
brain [1]. PTH regulates circulating and intracellular calcium levels, and may induce apoptosis
due to calcium overloading [2]. Elevated PTH levels are associated with reduced regional cere-
bral blood flow [3], whereas PTH-related protein (PTHrP) inhibited calcium channel activity
via the PTH/PTHrP receptor may contribute to maintaining normal neuronal function (for ex-
ample by increasing resistance to excitotoxic injury) [4]. PTH also promotes the conversion of
vitamin D to its active form (1,25-dihydroxyvitamin D) [5], which an emerging body of evi-
dence suggests may be neuroprotective [6, 7].
Hyperparathyroidism, characterized by elevated/high PTH levels, has been associated with
many chronic conditions including impaired cognitive function and dementia [8–11]. Patients
with primary hyperparathyroidism (high PTH and calcium levels), the most common parathy-
roid disease, often report cognitive complaints and observational studies have described poorer
cognitive function in those patients compared to control groups including impaired perfor-
mance in memory and attention tasks [12, 13]. Although not supported by all studies [14, 15],
there is evidence from surgical studies that parathyroidectomy, which if successful leads to nor-
malization of PTH and calcium levels, is associated with significant improvement in cognitive
function [9, 16, 17] or even reversibility of cognitive deficits [12]. Secondary hyperparathyroid-
ism is determined by high PTH levels, normal to low calcium levels and concurrent decrease in
vitamin D levels. Failing kidneys may cause secondary hyperparathyroidism and therefore the
condition is frequently occurring in chronic kidney disease. Cognitive impairment has also
been observed in this parathyroid condition [18] followed by postoperative improvement [10].
Moreover, recent findings suggest that elevated PTH levels may be associated with increased
risk of cognitive decline and incident dementia [19]. Elevated PTH concentrations in dementia
patients have been documented as well [20, 21]. There is some indication that hypoparathy-
roidism (low serum PTH and calcium levels) may be associated with poorer cognitive function
too [22, 23]. Existing narrative reviews [24, 25] are inconsistent and do not provide a compre-
hensive picture as they have focused on primary hyperparathyroidism and the effects of sur-
gery on cognition. Even though the need to understand the nature of the associations between
hyperparathyroidism and cognition or indeed PTH as a potential index of cognitive im-
pairment or dementia has been recognized [26], there is no systematic evaluation of all the
available evidence in this area to inform current knowledge and future research needs. There-
fore, our aim was to conduct a systematic review to update and evaluate the current research
for the association of PTH and parathyroid conditions with cognitive function and dementia.
Methods
Literature search
The systematic review was conducted following the general principles published by the NHS
Centre for Reviews and Dissemination [27]. A predefined protocol was developed following
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consultation with experts in the field (S1 Text). The following electronic databases were
searched for relevant studies from inception to January 2014: Medline, Embase, PsycINFO,
HMIC, CINAHL, AMED, Web of Science, and the Cochrane Library of Systematic Reviews.
The search strategies used text words and relevant indexing (MeSH terms) to identify studies
on the association between parathyroid hormone, cognition function and dementia. The search
terms parathyroid, hyperparathyroidism, parathormone, cognitive (function or decline or im-
pairment or assessment or change), memory, neuropsychological (assessment or evaluation or
test), Alzheimer, and (vascular or frontotemporal or Lewy bodies) dementia were used (full
strategy in supplementary data). Forward and backwards citation searching was used to identi-
fy any additional relevant studies. The journal Surgery (January 1995-January 2014) and the
Journal of Clinical Endocrinology & Metabolism (January 1997-January 2014) were electroni-
cally “hand”- searched, having been identified as important journals in the field. Internet
searches were performed on the following websites: Alzheimer’s Society (www.alzheimers.org.
uk), Alzheimer’s Research UK (www.alzheimersresearchuk.org), Alzheimer’s Association
(www.alz.org) and Hypoparathyroidism UK (www.hpth.org.uk). The section of each website
labeled “Research” or research related tabs (e.g. ‘research portfolio’, ‘researchers and profes-
sionals’) were reviewed in detail (IL).
Study selection
Studies were included if they investigated the association of parathyroid hormone with cogni-
tive function or dementia measured by widely used neuropsychological tests or international
diagnostic criteria. Studies evaluating the relationship between parathyroid hormone and cog-
nitive variables assessed only by self-report measures were excluded from the systematic re-
view, as were case-reports, narrative reviews, letters and editorials that did not include original
research findings. There was no restriction in study design or language of publication. The titles
and abstracts retrieved by the electronic search were screened independently by two reviewers
(IL & MS). The full text of potentially relevant papers was retrieved and screened the same
way. Any discrepancies were resolved with the involvement of a third reviewer (DJL).
Data extraction and quality assessment
A customized data extraction form with versions to match different study designs was devel-
oped, pilot tested on four included studies and refined accordingly. Data on study and partici-
pant characteristics, intervention/exposure, parathyroid hormone, covariates, method of
cognitive assessment and relevant outcomes were extracted by one reviewer (IL) and checked
by the second reviewer (MS). We attempted to contact corresponding authors of studies where
relevant data was not reported; one author responded but was not able to provide additional
data [35]. The quality of the design and reporting of included studies was assessed in the same
way using the Downs and Black checklist, a reliable and valid quality index for the appraisal of
both randomized and non-randomized studies [28]. Discrepancies were resolved through dis-
cussion (IL & MS).
Data synthesis
The main findings have been summarized in narrative form. A meta-analysis was not possible
due to great variability in cognitive assessment tools and omitted or underreported relevant
data. The results are categorized broadly by nature of exposure (i.e. surgical and non-surgical
studies) and type of parathyroid condition. Within each condition synthesis is presented by
study design and further by the most commonly assessed cognitive outcomes across studies.
These included global cognitive function, memory, executive function, attention, dementia
PTH and Cognitive Function
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and a category for tests assessing other cognitive domains (for example, visuospatial skills,
verbal fluency or other). For studies reporting more than one type of research design (i.e. pre-
post surgery and baseline case-control comparisons), the more robust study design was in-
cluded in the synthesis (additional relevant results for each study can be found in S1 Table. A
p value< 0.05 was considered statistically significant. One study provided inadequate data for
pre-post comparisons and since it was difficult to estimate the nature of changes, a measure of
cognitive impairment constructed by the authors expressed in frequencies was used in the
synthesis of results.
Results
The systematic search of all databases yielded a total of 1633 references. Duplicates were
checked and excluded (n = 614). Title and abstract screening resulted in the exclusion of a fur-
ther 971 papers. Full texts of the remaining 48 papers were obtained for detailed review. Twen-
ty-one papers were excluded following full text screening: one case-report, five studies based
on self-report measures of cognitive symptoms and three meeting abstracts with insufficient
data for analysis; ten further papers were excluded as they did not actually report comparisons
between PTH levels or parathyroid conditions and cognitive function or dementia. No addi-
tional relevant papers were identified via the supplementary searches (forward and backwards
citation, journal ‘hand’-searches and website searches). Twenty-seven papers were eligible for
inclusion (Fig 1).
Study characteristics
Study characteristics are shown in Table 1. Studies were published between 1978 and 2013;
most of them were conducted in Europe and the United States with the remainder in Australia
and Asia. Study designs identified were: one randomized controlled trial [15], one prospective
study [19], fourteen observational studies pre- and post parathyroidectomy [9, 10, 12–14, 16,
17, 29–35], four cross-sectional [18, 36–38] and seven case-control studies [20–23, 39–41].
One study reported data for two parathyroid conditions [29]. Population sizes ranged from 10
to 457 individuals and involved adults mainly recruited from hospitals and endocrine surgery
units. The majority of studies included middle-aged populations (50 years or older). Four stud-
ies included only women [12, 20, 21, 40] and one study included only men [29]. There were
two studies [13, 19] with a follow-up period longer than 6 months, whereas most studies had
short-term or medium-term follow-up (less than 6 months).
Assessment of parathyroid hormone
Serum PTH levels were biochemically confirmed by radioimmunoassay methods. Pre- and
postoperative mean PTH levels were reported in nine studies [9, 10, 12, 13, 15, 16, 31, 32, 35].
Three studies reported only preoperative mean PTH levels [14, 33, 34]. The majority of studies
used a PTH-level reference range of 10–69 pg/ml for patients without kidney disease, whereas
it varied across the studies with samples of patients on dialysis [10, 18, 36–38]. More specifical-
ly, primary hyperparathyroidism was defined based on normal, elevated or high PTH levels
but elevated calcium levels and normal serum creatinine levels. Secondary hyperparathyroid-
ism was generally (where reported) determined according to dialysis status, high PTH levels
but low/normal calcium levels, and serum creatinine or drugs influencing levels of calcium
(e.g. vitamin D analogs). Hypoparathyroidism patients were identified through a diagnosis of
hypoparathyroidism documented by low PTH levels and hypocalcaemia [22] or normal serum
creatinine and hyperphosphataemia in addition to those markers [23] (exact biomarker levels
not reported).
PTH and Cognitive Function
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Assessment of cognitive function and dementia
Forty-eight different tests and subtests were used across studies to assess cognitive function
(S2 Table). Ten studies utilized neuropsychological batteries, and the Wechsler Adult Intelli-
gence Scale (WAIS), the Trail making Tests A and B, and the Stroop Color-Word test seemed
to be the predominant tests. The rest of the studies used between one and four tests that mea-
sured cognitive abilities in specific domains, such as memory, attention and executive function.
The only common characteristic across studies is that they all measured some aspect of memo-
ry (e.g. visual, verbal or working memory). Screening tests to detect mild cognitive impairment
were administered in three studies [10, 16, 19]; two used the Mini Mental State Examination
Fig 1. Flow diagram of the selection process of studies included in the systematic review.
doi:10.1371/journal.pone.0127574.g001
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Table 1. Key characteristics of studies relating to PTH levels, parathyroid conditions, cognitive function and dementia.
Exposure and study Study design;
follow-up
length
Country Sample size,
N
Mean age (years) Outcomes and cognitive domains
examined
Covariates adjusted for in
analysis
Surgical intervention studies
Primary
hyperparathyroidism
Perrier [15] RCT; 6 weeks, 6
months
USA 18 Age range 54–83 Cognitive impairment in memory,
attention, processing speed, executive
functions
NR
Chianga[14] Pre-post; 30–
380 days
Australia 40 52 Cognitive impairment in memory,
attention, processing speed, executive
functions
NR
Cogan [29] Pre-post;4
months
USA 12 Cases: 59 Controls:
54
Cognitive impairment in global cognitive
function, memory, attention, visuospatial
skills, executive functions
NR
Dotzenratha [16] Pre-post; 6
months
Germany 52 Cases: 62 Controls:
61
Cognitive impairment in memory,
attention, visuospatial skills, executive
functions
NR
Goyala [29] Pre-post; 1 & 6
weeks, 3 & 6
months
India 39 Age range 18–60 Cognitive impairment in global cognitive
function & memory,
NR
Numanna [17] Pre-post; 4
months
USA 20 Cases: 63 Controls:
56
Cognitive impairment in memory,
attention, verbal abilities, visuospatial
skills, planning
NR
Romana [9] Pre-post & Case
control; 2–4
weeks
USA 41 Cases: 59 Controls:
51
Cognitive impairment in memory &
learning
Age, gender, serum calciume,
TSH levels
Walkera [12] Pre-post; 6
months
USA 128 Cases: 61 Controls:
56
Cognitive impairment in memory,
attention, intellectual ability, nonverbal
abstraction
Age, sex, education, estimated
IQ, anxiety, depression
Babinskaa [13] Pre-post; 12–18
months
Poland 70 Cases:52 Controls:
52
Cognitive impairment in memory,
attention, executive functions, flexibility
and planning, verbal fluency
Depression
Casella [34] Pre-postb; 1
month
Italy 16 72 Global cognitive function/impairment in
MMSE
Age, education
Mittendorfa [33] Pre-postb; 4
weeks
USA 47 63 Cognitive impairment in attention,
processing speed, executive function
NR
Prager[32] Pre-postb; 6, 12
weeks
Austria 20 61 Cognitive impairment in memory,
attention/concentration
Age, gender, serum calciume
Roman [31] Pre-postb; 1, 3 &
6 months
USA 159 60 Cognitive impairment in memory &
learning
NR
Benge [35] Pre-postb; 1
month
USA 67 61 Cognitive impairment in memory,
learning, attention, processing speed,
executive functions, verbal fluency,
dexterity
NR
Secondary hyperparathyroidism
Choua, d[10] Pre-post; 12, 16
weeks
Taiwan 62 Cases: 56 Controls:
60
Global cognitive function/impairment in
MMSE/CDR
NR
Cogand [29] Pre-post; 4
months
USA 11 Cases: 51 Controls:
54
Cognitive impairment in global cognitive
function, memory, attention, visuospatial
skills, executive functions
NR
Non-surgical studies
Serum PTH levels
Björkmana [19] Prospective; 1,
5, 10 years
Finland MMSE/
CDR433/
457-/304138/
141
81 Cognitive decline in MMSE Dementia
rating in CDR
Age, gender, baseline
cognition, serum ionized
calcium, creatinine, ApoE ε4
Kalaitzidisd [36] Cross-sectional Greece 256 58c Cognitive impairment in MMSE, Clock-
drawing test
Age, CKD stage, diabetes
mellitus, PTH
Ogiharaa [21] Case-control Japan 60 Non-dementia:
80AD: 81, VaD: 80
Alzheimer’s disease, Vascular dementia,
cognitive impairment
NR
(Continued)
PTH and Cognitive Function
PLOS ONE | DOI:10.1371/journal.pone.0127574 May 26, 2015 6 / 16
(MMSE) and the Clinical Dementia Rating scale [10, 19]. All-cause dementia and Alzheimer’s
disease were confirmed by standardized diagnostic criteria (DSM, NINCDS-ADRDA) and one
study used the Dementia Screening Scale of Hasegawa score [21]. Vascular dementia was diag-
nosed according to the NINDS-AIREN criteria and the guidelines by Erkinjuntti [42].
Quality assessment
Assessment of methodological quality (see S3 Table) was challenging because the reporting
was often incomplete. No study met satisfactorily all the quality indicators from the checklist
(reporting, internal and external validity, power) or received a high quality rating. Studies were
almost uniformly distributed in the low [14–18, 20, 21, 29, 30, 32, 34–36, 40] and moderate [9,
10, 12, 13, 19, 22, 23, 31, 33, 37–39, 41] quality categories. All but one [15] of the studies were
observational. The only randomized control trial retrieved [15] was a small pilot study with an
unsuccessful intervention and incomplete reporting of cognitive outcomes, and it does not con-
tribute significantly to the body of evidence. Although study objectives were clearly described
in all but three studies [21, 39, 41], the representativeness of the study population was often dif-
ficult to determine. Only five studies reported power calculations [9, 12–14, 31] and as study
Table 1. (Continued)
Exposure and study Study design;
follow-up
length
Country Sample size,
N
Mean age (years) Outcomes and cognitive domains
examined
Covariates adjusted for in
analysis
Johansson [39] Case-control Sweden 69 AD: 74Other
dementias:74 MCI:
72 Controls: 75
Alzheimer’s disease, Vascular dementia,
other dementias, stable mild cognitive
impairment
NR
Kipen [20] Case-control Australia 60 Cases: 76 Controls:
72
Alzheimer’s disease, all-cause dementia NR
Shore [40] Case-control USA 20 Cases: 76 Controls:
71
Alzheimer’s and non-Alzheimer’s type
dementia, mental status
NR
Secondary hyperparathyroidism
Driessend [37] Cross-sectional Germany 59 53 Global cognitive function in MMS NR
Gillid [18] Cross-sectional Italy 54 51 Cognitive performance in global cognitive
function & memory
NR
Leinaud [38] Cross-sectional USA 109 61 Global cognitive function in MMSE,
executive dysfunction
NR
Jordea [41] Case-control Norway 84 Cases: 62 Controls:
63
Cognitive impairment in memory,
attention, processing speed, executive
functions, verbal fluency
Age, gender, education, BMI,
health score, serum calcium,
serum 25-hydroxyvitamin De
Hypoparathyroidism
Aggarwal [23] Case-control India 132 Cases: 37 Controls:
37
Cognitive impairment in global score
combining 10 cognitive tests for attention,
memory, orientation, language, visuo-
spatial functioning, executive function,
verbal quotient
NR
Kowdley [22] Case-control USA 22 55 Cognitive impairment in memory,
concentration & attention, perceptual
organization, verbal fluency & learning
NR
MMSE: Mini Mental State Examination; CDR: Clinical Dementia Rating scale; MMS: Mini Mental State, NR: Not reported; CKD: chronic kidney disease.
a:Study reporting results for more than one type of research design (i.e. prospective/pre-post and cross-sectional or case-control) but basic characteristics
are the same, therefore only prospective designs are included here.
b: No control group.
c: mean age of six groups.
d: studies included participants undergoing dialysis.
e:unclear whether calcium /vitamin D is treated as a potential covariate or one of the predictors in linear regression models.
doi:10.1371/journal.pone.0127574.t001
PTH and Cognitive Function
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sizes were generally small, it is possible they had insufficient power to detect associations or
change in cognitive measures. Potential confounders were poorly described and rarely adjusted
for in the analyses (see Table 1). Details of participants lost to follow-up were underreported
and complete case analysis appears to be the method used to deal with missing data. Taken to-
gether, incomplete reporting, small sample sizes and inadequate adjustment for confounders
have potentially compromised the internal and external validity of the included studies.
Main findings
Surgical intervention studies. Primary hyperparathyroidism. Thirteen studies examined
the relationship between primary hyperparathyroidism and cognitive function (Table 2). These
comprised one randomized controlled trial and twelve pre-post surgery studies (8 with controls
and 5 without). The randomized controlled trial incorporated 9 patients in the surgery and
control group respectively followed for 6 months [15]. Changes on ten cognitive tests in this
small trial were not fully reported. Although a significant ‘change’ in the Stroop Word test was
reported at 6 months postoperatively (p = 0.02), it is not clear whether this change was ob-
served for both surgical patients and controls, or whether this change represented improved or
poorer cognition in comparison with baseline.
Table 2. Main findings of surgical intervention studies relating to parathyroid conditions, cognitive function and dementia.
Exposure and Study Study
design
Global cognitive
function
Memory Executive
function
Attention Other cognitive
domain
Dementia
Primary hyperparathyroidism
Perrierc [15] RCT — - —? —
Chianga,d [14] Pre-post — - - —
Cogan [29] Pre-post - — — - —
Dotzenratha§ [16] Pre-post " "- -
Goyala [29] Pre-post - -
Numanna,c,d [17] Pre-post " " "— - " " "—
Romana,c,d [9] Pre-post "—-
Walkera,c,d [12] Pre-post " " "— "— -
Babinskaa [13] Pre-post " "— - - —
Casella [34] Pre-postb -
Mittendorfa[33] Pre-postb " " "
Prager [32] Pre-postb " " "—
Roman [31] Pre-postb " " " " "
"
Benged[35] Pre-postb "
Secondary
hyperparathyroidism
Global cognitive
function
Memory Executive
function
Attention Other cognitive
domain
Dementia
Choua[10] Pre-post " "
Cogan [29] Pre-post - — " " - " "
Note: Empty cells indicate no relevant results. Arrows and dashes indicate the number of tests conducted under each domain.
a Study reporting results for more than one type of research design (e.g. prospective and cross-sectional, pre-post surgery and case-control, see S1
Table).
b: Pre-post surgery study with no control group.
c: Total number of tests used or comparisons made not clearly reported.
d: P values not fully reported.
": Postoperative improvement compared to controls (p <. 05) indicating elevated PTH levels were harmful.
–: No statistically significant association/difference (p <. 05) observed in tests.
?: Direction of change unclear.
doi:10.1371/journal.pone.0127574.t002
PTH and Cognitive Function
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Eight of the observational studies of primary hyperparathyroidism compared patients receiv-
ing parathyroidectomy to controls. Five out of these eight studies reported significant improve-
ment of surgical patients in comparison with controls on at least one cognitive test [9, 12, 13, 16,
17] although the precise number of tests incorporated was unclear in two studies [9, 17]. The re-
sults of statistical significance tests were not fully or adequately reported in five studies [9, 12,
14, 16, 17]. Three studies that measured global cognitive function provide mixed results; two
showing no change [29, 34] and one reporting significant postoperative improvement [16].
Memory was assessed in all eight studies. Five studies reported improvement on one to three
memory subtests incorporated in their assessments [9, 12, 13, 16, 17] (Table 2). Yet, memory
improvement was not universal within a given study which is reflected by the nineteen memory
tests/subtests with no postoperative change. None of the five studies that examined executive
function observed changes postoperatively [13, 14, 16, 17, 29], whereas attention was improved
postoperatively in one [12] out of four studies [12–14, 29]. Other areas with better postoperative
performance among the numerous tests utilized across studies included abstract verbal reason-
ing, visual processing and spatial perception as measured by theWAIS scale [17].
Three out of the five studies pre-post parathyroidectomy without a control group reported
significant improvement on at least one cognitive measure [13, 31–33] (Table 2). One study re-
ported no significant change in global cognitive function [34]. Memory performance was im-
proved significantly in two studies [31, 32] and executive function in one study [33].
Postoperative improvement in attention tasks was observed in two studies [32, 33]. Finally, one
pre-post study [35] categorized patients having clinically significant impairment if their perfor-
mance on three or more of fifteen cognitive tests was below a z-score of 1.5. Nearly 40% of pa-
tients who met the criteria for clinically significant impairment preoperatively were no longer
impaired a month after parathyroidectomy. Information processing speed was the main do-
main with significant change. This is also the only study reporting decline at follow-up. 18.6%
of patients were found impaired postoperatively, mainly on memory and fewer on executive
function measures [35].
Despite that these studies [31–35] support a beneficial effect of parathyroidectomy and
therefore reduction of PTH levels on cognitive outcomes, the lack of a control group and the
short-term follow-up do not allow differentiation between improvements due to surgery and
improvements due to practice effects. Taken together, studies of primary hyperparathyroidism
provide mixed evidence to support an association with poorer memory and other cognitive
domains.
Secondary hyperparathyroidism. Both pre-post studies [10, 29] examined the effect of
parathyroidectomy on global cognitive function, but only one demonstrated improved perfor-
mance after surgery [10]. The study also reported improved dementia rating scores (global)
measured by the CDR scale following surgery for the study group compared to controls with
secondary hyperparathyroidism; memory was the domain with the greatest postoperative im-
provement [10]. No postoperative difference was observed in tests of memory and attention
but parathyroidectomy was associated with improvement in executive function, visual-motor
skills and scoring of general intelligence items in the second study [29].
Non-surgical studies
Serum PTH levels. Six studies examined the relationship between serum PTH levels and
cognitive function [19, 36, 39, 40] or dementia [19–21, 39, 40] (Table 3). Björkman and col-
leagues [19] conducted the only prospective study. Participants with elevated PTH levels
(62ng/L; normal<55 ng/L) had a two-fold increased risk of cognitive decline and all-cause
dementia over one and five years [19]. No associations were observed at the 10-year follow-up,
PTH and Cognitive Function
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though non-random attrition on the basis of baseline PTH levels was observed and the sample
size was greatly reduced by that point. This suggests that PTH elevation may precede cognitive
decline. However, around 36% of participants already had cognitive impairment at baseline
and therefore reverse causation is possible. One cross-sectional and four case-control studies
also provide some support for an association between serum PTH and poor cognitive function/
impairment or dementia. Higher serum PTH was associated with poorer performance on mea-
sures of global cognitive function and executive function in the cross-sectional study [36].
Findings from two case-control studies showed no significant difference in PTH levels between
groups of patients with Alzheimer’s disease, other dementias, cognitive impairment and con-
trols [39], or between patients with Alzheimer’s disease and a mixed control group with other
type of dementia or a psychiatric illness [40]. Conversely, two additional case-control studies
reported significantly higher serum PTH in women with dementia compared to controls [20,
21]. The results of statistical significance tests were not fully or adequately reported in two
studies [36, 40]. In summary, mixed findings for both cognitive function and dementia were
suggestive of an association with higher PTH levels though equivocal.
Secondary hyperparathyroidism. Four non-surgical studies examined the relationship
between secondary hyperparathyroidism and a number of cognitive domains [18, 37, 38, 41]
(Table 3). All but one [41] of the studies were conducted in patients with chronic kidney
Table 3. Main findings of non-surgical studies relating to PTH levels, parathyroid conditions, cognitive function and dementia.
Exposure and Study Study design Global cognitive
function
Memory Executive
function
Attention Other cognitive
domain
Dementia
Serum PTH levels
Björkmana[19] Prospective # #
Kalaitzidisb [36] Cross-
sectional
# #
Johansson [39] Case-control - -
Ogihara [21] Case-control #
Kipen [20] Case-control #-
Shoreb [40] Case-control - -
Secondary
hyperparathyroidism
Global cognitive
function
Memory Executive
function
Attention Other cognitive
domain
Dementia
Driessenc [37] Cross-
sectional
#
Gillic [18] Cross-
sectional
# #
Leinauc [38] Cross-
sectional
- #
Jordea [41] Case-control #——— — #—- #
Hypoparathyroidism Global cognitive
function
Memory Executive
function
Attention Other cognitive
domain
Dementia
Aggarwal [23] Case-control # # # #— # # # -
Kowdley [22] Case-control ——— —— #—
Note: Empty cells indicate no relevant results. Arrows and dashes indicate the number of tests conducted under each domain.
a: Study reporting results for more than one type of research design (e.g. prospective and cross-sectional, pre-post surgery and case-control).
b: P values not fully reported.
c: studies included participants undergoing dialysis
#: Poorer performance compared to controls or in relation to PTH (p <. 05) indicating abnormal PTH levels are harmful.
–: No statistically significant association/difference (p <. 05) observed in tests.
doi:10.1371/journal.pone.0127574.t003
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disease, however this did not appear to be accounted for in the analyses. All three cross-section-
al studies [18, 37, 38] in this group assessed global cognitive function; two studies [18, 37] re-
ported that higher mean PTH levels were significantly associated with poorer cognitive
performance. Memory was assessed in two studies [18, 41]: the cross-sectional study found
worse performance in a memory scale for those with higher PTH levels [18]. The case-control
study [41] reported that patients with secondary hyperparathyroidism showed poorer perfor-
mance in one out of seven tests of memory (i.e. working memory) compared to the age- and
sex-matched control group. Patients’ performance was also found to be significantly different
in one out of four tests of attention. Another area that appears to be influenced was language.
No difference between groups was found in this study in two executive function tests [41]. By
contrast, cross-sectional results showed that elevated serum PTH was associated with executive
dysfunction in one study [38]. Taken together, evidence from non-surgical studies suggests
some degree of cognitive impairment in patients with secondary hyperparathyroidism. No
consistent pattern related to specific cognitive domains could be identified in this condition.
Hypoparathyroidism. Two case-control studies in hypoparathyroidism [22, 23] provide
limited evidence to suggest increased odds of cognitive dysfunction (Table 3). Both studies
used multiple tests covering a range of cognitive domains. Patients had poorer performance on
at least one test in comparison with matched controls. Verbal fluency test (out of 10 tests in
total) was significantly different compared to controls in one of the studies [22]. The second
study observed poorer performance for patients across multiple domains including global cog-
nitive function, verbal and visual memory, executive function, attention, and visuospatial skills
[23].
Role of calcium and vitamin D
Calcium was hypothesized to be a potential confounder in one study [19] and a potential
mechanism to explain the association between PTH and cognitive dysfunction or dementia in
sixteen studies [9, 10, 13, 14, 16, 17, 21, 22, 29, 31, 32, 34, 35, 37, 39, 41]. Only one study adjust-
ed for ionized calcium as a potential confounder though the association between PTH and cog-
nitive decline at one and five years remained [19]. Although three studies [9, 32, 41] reported
including calcium levels in regression models, it is unclear whether they treated calcium as a
potential confounder or one of the predictors of cognitive function in the statistical models. In
a case-control study of hypoparathyroid patients the degree of cognitive dysfunction was relat-
ed to the degree of intracranial calcification on computed tomography [22]. Postmortem brain
calcium levels were also significantly higher in patients with chronic renal failure and second-
ary hyperparathyroidism in comparison with controls [29]. Vitamin D was proposed to be a
potential confounder in two studies [15, 37], and a potential mechanism in seven studies [13,
19–21, 35, 39, 41]. However, no study actually adjusted for serum vitamin D levels as a poten-
tial confounder or investigated vitamin D as a potential mechanism in their models. In general
the reporting of these important covariates when they were included was inadequate, and their
potential role in relation to PTH, cognition and dementia remains largely unclear.
Discussion
This systematic review synthesized 27 low and moderate quality studies of PTH and parathy-
roid conditions in relation to cognitive function or dementia. Considerable heterogeneity of
study designs, populations, sample size, outcomes and statistical analyses prevented a quantita-
tive synthesis of the results in a meta-analysis. Furthermore, studies were challenging to syn-
thesize due to inadequate reporting. Serum calcium and vitamin D were conceptualized
inconsistently as both confounders and causal mechanisms though were not generally
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incorporated in analyses. No large, well-designed trial has investigated whether normalizing
PTH levels is effective at improving cognitive outcomes or reducing the risk of dementia. Find-
ings from observational studies were generally mixed, and offer weak support for a link be-
tween PTH and cognitive function or dementia.
The majority of identified studies examined primary hyperparathyroidism and the effect of
surgery on cognition (n = 13) providing mixed results for a link with cognitive function. The
wide range of cognitive measures and the limited use of global screening tools have contributed
to inconsistencies and an irregular pattern of associations. Other than findings of some im-
provements in various aspects of memory in seven of the thirteen studies in this condition,
changes in other cognitive domains—if present- seem to follow a random pattern. Even so, the
potential independent role of PTH as opposed to important covariates such as calcium and vi-
tamin D was not systematically investigated. Only two studies [9, 31] provided evidence to sup-
port an association between higher PTH levels and poorer cognitive function in primary
hyperparathyroidism. Similarly, studies in secondary hyperparathyroidism (where we see high
PTH but low calcium and vitamin D levels) showed some evidence for impaired cognitive
function. Kidney function, however, was generally not adjusted for in these studies as a poten-
tial confounder (e.g. statistical adjustment for glomerular filtration rate in the analysis [19]).
Again, the pattern of changes was rather inconsistent and it is based on a small number of stud-
ies of observational nature (cross-sectional and case-control) and poor quality [18, 37, 38, 41].
The review also suggests that potential associations with cognition may not be limited to hy-
perparathyroidism but extent to generally abnormal PTH levels. Thus, low PTH may have a
negative influence on cognition as indicated by the two small case-control studies in hypopara-
thyroidism [22, 23]. Studies of serum PTH levels and cognitive function are limited and evi-
dence from high quality data is lacking. Associations with dementia risk are understudied.
Only one long-term prospective study was identified [19] supporting a link between higher
PTH levels and increased risk of dementia. Currently, this study [19] along with the surgical in-
tervention studies by Roman and colleagues [9, 31] concentrate the evidence to support a po-
tentially independent role of PTH in cognition and dementia. Certainly more research is
needed to confirm this hypothesis. Indeed, PTH excess has been associated with various health
outcomes and has the potential to influence cognitive function and dementia risk but the un-
derlying mechanisms to explain such relationships, although suggested, were not actually ex-
plored in the reviewed studies (e.g. using mediation analysis).
Several mechanisms have been proposed to explain possible links between PTH, cognitive
decline and dementia. Traditionally, impaired cognition in primary hyperparathyroidism has
been attributed to hypercalcaemia. High serum calcium levels have been associated with faster
decline in cognitive function in the elderly [43]. It is hypothesized that calcium ions cross the
blood-brain barrier which may result in calcium overload, neuronal signaling disruption or at-
rophy in hippocampus and Alzheimer’s disease [2]. Calcium deposits in the brain have also
been related to frontal-subcortical dementia [44]. Furthermore, PTH is related to vitamin D lev-
els and as both regulate calcium levels, they are linked through a feedback loop; decreasing
serum vitamin D levels are associated with increasing PTH levels. Long-term vitamin D defi-
ciency may induce secondary hyperparathyroidism and is also associated with increased risk of
cognitive decline and Alzheimer’s disease [45]. A recent meta-analysis indicated that higher
PTH levels were associated with nearly 50% increased risk of cardiovascular disease events [46].
Arterial stiffness and endothelial dysfunction have been observed in patients with primary hy-
perparathyroidism and may result in cognitive impairment [47]. PTH crosses the blood-brain
barrier and PTH excess in animal models has been linked to enhanced release of vasopressin
and vasoconstriction [48]. Additionally, hypoperfusion in several cortical regions involved in
memory and learning has been observed in patients with primary hyperparathyroidism
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compared to controls [3]. Normalization of PTH levels may influence brain metabolism and
may be responsible for the postoperative improvement in cognition demonstrated in patients
with primary hyperparathyroidism.While a range of different mechanisms have been proposed
their possible clinical relevance is unclear and remains to be established.
Our analysis is the first systematic review to examine associations between PTH, cognition
and dementia, covering the whole spectrum of parathyroid conditions and also serum PTH lev-
els. The review was based on a comprehensive search strategy without date or language restric-
tions, which supports our confidence in identifying all relevant studies. Whilst the broad scope
of the review provides a comprehensive picture of current research in this area, it has intro-
duced some heterogeneity. Additionally, owing to the observational nature of all but one of the
studies the issue of causality cannot be assessed. Only one randomized controlled trial has been
conducted of limited sample size and follow-up. The majority of studies incorporated small
sample sizes and are likely to have lacked statistical power to detect associations or significant
change. Multiple testing was an issue as many studies incorporated a large number of cognitive
tests. Given the low to moderate quality and generally inadequate reporting, it is not possible to
draw firm conclusions about the relationship between PTH and cognitive function or demen-
tia. The range of cognitive outcomes, inadequate reporting and methodological heterogeneity
meant that it was not possible to conduct a meta-analysis which would have made it easier to
estimate if there was a significant pooled association across studies.
Conclusions
In conclusion, there is currently no basis to suggest a causal relationship between PTH and cog-
nitive function or dementia. Mixed findings from the available studies are supported by low
and moderate quality data susceptible to confounding effects and limited external validity. To
date, no trial has examined this relationship where PTH levels were successfully normalized in
a large population at risk of dementia. Given the plausible mechanisms to suggest abnormal
PTH levels may lead to cognitive dysfunction and an increased risk of dementia, further inves-
tigation is warranted. Large well-designed prospective studies would be useful and could also
investigate related factors including calcium and vitamin D which have been conceptualized as
both confounders and causal mechanisms in the previous literature.
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